Efficacy, Safety, and Tolerability of NBI-1065890 Versus Placebo in Adults With Tardive Dyskinesia

Recruiting now · Phase 2 · Has a placebo group

Conditions studied: Tardive Dyskinesia

In brief

The primary objective of this study is to evaluate the efficacy of NBI-1065890 compared with placebo for the treatment of tardive dyskinesia (TD) in adult participants.

Key facts

Study ID
NCT07365462
Run by
Neurocrine Biosciences
People needed
100
Starts
2026-02-06
Expected to finish
2027-03-01
Last updated by the study team
2026-06-23

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.